Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.

Inclusion Criteria: 1. Male or Female, at least 18 years of age 2. Subject is able to swallow pills and use ReX-C device to receive medication. 3. Subject is able to read and understand the Informed Consent Form. 4. Subject receives anti-coagulants for the treatment and prevention of thromboembolism events, (e.g: Arterial Fibrillation (AF), Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)). 5. Subject receives Novel Oral Anti-coagulant (NOAC); including; Pradaxa® (dabigatran), Xarelto® (rivaroxaban) and Eliquis® (apixaban). 1. Subject is recruited at least 1 month after treatment initiation and has stable dose regime. 2. Subject receives stable dose of medication for at least a month. 6. Subject takes medication therapy at home. Exclusion Criteria: 1. Subject has significant physical disability including; poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent Form or use the ReX-C dispensing unit effectively. 2. Subject cen not use ReX-C to receive medications. 3. Subject is participating in another clinical study that does not permit participation in two studies simultaneously. 4. Subject is at end stage or terminal illness with anticipated life expectancy of 6 months or less. \-